In a double-blind, cross-over trial, the biochemical and haemodynamic effects of nicergoline* * Nicergoline - Sermion,® Farmitalia Carlo Erba, Milan., an ergoline derivative, administered at a dosage of 60 mg daily were evaluated and compared with placebo in 14 parkinsonian patients treated with levodopa + dopadecarboxylase inhibitors by monitoring blood pressure, heart rate, plasma catecholamine, insulin and glucose peri-prandial fluctuations as well as responses to the tilt-table test of blood pressure and heart rate. After the first administration of nicergoline, asymptomatic postural hypotension was recorded in two patients, with a good tolerance developing by the end of the first 7-day period of treatment. Nicergoline appeared not to influence haemodynamic and biochemical changes induced by the ingestion of a standard meal. The results show the necessity of evaluating recurrence of orthostatic and/or post-prandial hypotensive events in each parkinsonian patient basally at the beginning of therapy or during standard treatment with levodopa before new pharmacological strategies are started, to determine patients at risk of clinical symptomatic hypotension.
|Number of pages||13|
|Journal||Clinical Trials Journal|
|Publication status||Published - 1987|
- cardiopressor adaptability
- Parkinson's disease
ASJC Scopus subject areas
- Pharmacology (medical)